Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Stopped Due to COVID-19 pandemic outbreak and its impact on overall study activities. All efforts were made to ensure that participants that were enrolled and/or were still in the study will continue to receive treatment and follow-up until study completion.

Conditions

• Granulomatosis With Polyangiitis (GPA)
• Microscopic Polyangiitis (MPA)

Interventions

• DRUG: IFX-1 low dose
• DRUG: IFX-1 high dose
• DRUG: Placebo

Sponsor

InflaRx GmbH

Collaborators

• [object Object]